ImmunityBio, Inc. (IBRX) Stock Price & Analysis
ImmunityBio, Inc. (IBRX) closed at USD 8.31 on Thursday, October 22, 2026, down 3.82% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 8.64; the Oct 22, 2026 session ranged USD 8.02–8.84 on volume of 12,731,345 shares. Market capitalization is $8.81B, with a 52-week range of USD 1.95–12.43 (NMS). Source: Nexqual, retrieved October 23, 2026 at 10:05 UTC.
Also available as compact Markdown for AI agents: nexqual.com/IBRX.md
Key facts (IBRX)
- Last four reported quarters (through Jun 30, 2026): revenue $166M, net income -$992M (-598.6% margin), free cash flow -$288M (SEC filings).
- Insider open-market sales, last ~7 months: 7 Form 4 filings, $5.0M; 0 not under a Rule 10b5-1 plan ($0K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 1.75 on a 1–5 scale) (4 analysts), mean target USD 14.25 (range 12–16).
- Total return with dividends: 1Y +247.7% vs S&P 500 +14.9%; 5Y +0.5% vs S&P 500 +80.3%.
- Next earnings: 2026-11-03, EPS estimate USD -0.05, revenue estimate $59.2M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (IBRX)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $934K | $240K | $622K | $14.7M | $113M | $166M |
| Gross profit | — | $240K | $622K | $14.7M | $113M | — |
| Operating income | -$330M | -$351M | -$362M | -$344M | -$256M | -$252M |
| Net income | -$347M | -$417M | -$583M | -$414M | -$351M | -$992M |
| EPS (diluted) | -$0.89 | -$1.04 | -$1.15 | -$0.62 | -$0.38 | — |
| Free cash flow | -$308M | -$416M | -$397M | -$398M | -$309M | -$288M |
| Gross margin | — | 100.0% | 100.0% | 100.0% | 99.3% | — |
| Operating margin | -35361.9% | -146374.2% | -58239.5% | -2334.2% | -226.0% | -151.9% |
| Net margin | -37129.6% | -173569.6% | -93761.4% | -2804.8% | -310.2% | -598.6% |
| Revenue growth | +54.4% | -74.3% | +159.2% | +2270.6% | +668.3% | — |
| Cash + short-term investments | $317M | $107M | $266M | $150M | $243M | — |
| Total debt | — | $241M | $577M | $1.2M | — | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (IBRX)
P/S 53.1x · FCF yield -3.27% · Earnings yield -11.27%
Insider sales (SEC Form 4, open-market, last ~7 months) (IBRX)
7 of 7 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-10-05 | Simon Barry J. | Director | 25,000 | $269K | 0.9% | Yes (adopted December 18, 2025) | Too little history (no open-market trades in 2023–2025) |
| 2026-10-02 | Cohen Cheryl | Director | 81,056 | $851K | 44.7% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-07-02 | Cohen Cheryl | Director | 131,210 | $1.2M | 51.1% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-07-01 | Selecky Christobel | Director | 159,478 | $1.4M | 100% | Yes (adopted March 13, 2026) | Too little history (no open-market trades in 2023–2025) |
| 2026-06-29…2026-06-30 | Selecky Christobel | Director | 96,722 | $871K | 100% | Yes (adopted March 13, 2026) | Too little history (no open-market trades in 2023–2025) |
| 2026-06-24 | Simon Barry J. | Director | 25,000 | $197K | 0.9% | Yes (adopted December 18, 2025) | Too little history (no open-market trades in 2023–2025) |
| 2026-06-04 | Simon Barry J. | Director | 23,033 | $165K | 0.8% | Yes (adopted December 18, 2025) | Too little history (no open-market trades in 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (IBRX)
Consensus Buy (mean 1.75 on a 1–5 scale), 4 analysts; mean target USD 14.25 (low 12, high 16).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-15 | Jefferies | Target raised | Buy | $12 → $14 |
| 2026-10-15 | HC Wainwright & Co. | Reiterated | Buy | $15 |
Total return (dividends reinvested) (IBRX)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +247.7% | +0.5% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +249.2% | +0.1% |
| Volatility (annualized) | 101.4% | 115.4% |
| Max drawdown | -42.3% (Feb 2026→Mar 2026) | -84.6% (Nov 2021→Sep 2023) |
IBRX revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Product revenue, net | $50.7M | 98.9% | +91.8% |
| Other revenues | $568,000 | 1.1% | +14100.0% |
| Total revenue | $51.2M | 100% | — |
IBRX revenue by region (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| United States | $50.7M | 99.0% | +91.9% |
| Europe | $518,000 | 1.0% | — |
| Total revenue | $51.2M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
IBRX suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | Merck (MRK) | “This addresses a significant supply challenge: TICE BCG (Merck) has been the sole supplier of BCG product in the U.S. since 2012, and rationing has been ongoing since 2019.” |
| Partner | NantWorks | “While we and our shared services partner, NantWorks, have invested, and continue to invest, in the protection of our data, systems, and infrastructure, there can be no assurance that our efforts, or the efforts of our partners, vendors, CROs, CMOs, clinical sites and other contractors and consultants, will be successful.” |
| Partner | 3M (MMM) | “3M IPC and AAHI License Agreement” |
Quoted from the company's 10-K filed Feb 23, 2026.
Companies that name IBRX in their SEC reports
| Relationship to IBRX | Company | Filing | Sentence |
|---|---|---|---|
| partner | HCW Biologics Inc. (HCWB) | 10-K Mar 31, 2026 | “The Company agreed to provide ImmunityBio with a right of first refusal to enter a licensing agreement for oncology indications for HCW9206.” |
IBRX customer concentration
In the period ended Jun 30, 2026, 4 direct customers each accounted for at least 10% (42%, 22%, 16%, 10%) of revenue, per the company's 10-Q filed Aug 4, 2026. The company does not name them.
IBRX analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.05 | $-0.07 | -28.6% | $59.2M | 3 |
| Next quarter (ends Dec 2026) | $-0.04 | $-0.05 | -13.3% | $72.0M | 3 |
| Current fiscal year (ends Dec 2026) | $-0.92 | $0.00 | — | $226.6M | 2 |
| Next fiscal year (ends Dec 2027) | $-0.07 | $0.06 | -222.2% | $471.9M | 3 |
IBRX options: expected move
Options price a move of about ±15.6% (±$1.30) by Nov 6, 2026, which includes earnings on Nov 3, 2026; the earnings reaction alone is priced at about ±9.1%. Over the last 8 reports the stock moved ±17.3% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Oct 30, 2026 | 7 | 79.0% | ±9.6% |
| Nov 6, 2026 | 14 | 95.1% | ±15.6% |
| Nov 13, 2026 | 21 | 106.3% | ±21.0% |
| Nov 20, 2026 | 28 | 119.5% | ±27.0% |
| Nov 27, 2026 | 35 | 138.1% | ±34.5% |
| Dec 18, 2026 | 56 | 101.7% | ±31.2% |
| Jan 15, 2027 | 84 | 101.4% | ±40.5% |
| Mar 19, 2027 | 147 | 91.6% | ±45.1% |
30-day implied volatility 95.9% vs 78.5% realized over the last 30 trading days. Put/call ratio (volume) 0.33. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 10:05 UTC)
| Price | USD 8.31 |
|---|---|
| Change | ▼ 3.82% (down) |
| Previous Close | USD 8.64 |
| Open | USD 8.51 |
| Day Range | USD 8.02 – 8.84 |
| 52-Week Range | USD 1.95 – 12.43 |
| Volume | 12,731,345 shares |
| Market Cap | $8.81B |
| Exchange | NMS |
Technical Analysis (IBRX)
Nexqual's technical model rates IBRX "SELL" based on 2 bullish and 4 bearish signals across 127 daily candles, as of October 23, 2026 at 10:05 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 42.05 (neutral) |
| vs SMA50 | Below (USD 8.63) |
| MACD | 0.03 (positive) |
Analyst Ratings (IBRX)
Wall Street analysts rate IBRX "Buy" based on 4 analysts, with a mean price target of USD 14.25 (range USD 12–16), per Nexqual as of October 23, 2026 at 10:05 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 14.25 |
| High Target | USD 16 |
| Low Target | USD 12 |
| Buy / Hold / Sell | 4 / 0 / 0 |
Earnings (IBRX)
| Next Earnings Date | 2026-11-03 |
|---|---|
| EPS Estimate | USD -0.05 |
| Revenue Estimate | $59.23M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.22 vs est -0.08 ▼ miss |
| 2026-03-31 | USD -0.08 vs est -0.07 ▼ miss |
| 2025-12-31 | USD -0.06 vs est -0.1 ▲ beat |
| 2025-09-30 | USD -0.07 vs est -0.1 ▲ beat |
Source: Nexqual, October 23, 2026 at 10:05 UTC.
Financials & Fundamentals (IBRX)
| Total Revenue | $165.79M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +93.90% |
| Gross Margin | +99.34% |
| Operating Margin | -120.41% |
| Profit Margin | +0.00% |
| Current Ratio | 5.72 |
| Total Cash | $357.37M |
| Total Debt | $1.23B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | -$288.07M (-173.8% of revenue) |
Source: Nexqual, October 23, 2026 at 10:05 UTC.
Financial Health Score (IBRX)
Nexqual rates ImmunityBio, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 10:05 UTC.
| Growth | Strong — Revenue +668% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $357M cash vs $1.23B debt |
| Cash Flow | Weak — FCF negative: -$288M (last 4 quarters to Jun 2026, SEC), burning cash |
| Efficiency | Mixed — No data |
Ownership (IBRX)
| Insider Ownership | +62.15% |
|---|---|
| Institutional Ownership | +19.79% |
| Shares Outstanding | 1.06B |
| Float | 406.69M |
| Short % of Float | +30.95% |
Source: Nexqual, October 23, 2026 at 10:05 UTC.
Leadership (IBRX)
ImmunityBio, Inc. is led by Richard Gerald Adcock, President, CEO & Director, per Nexqual as of October 23, 2026 at 10:05 UTC.
| President, CEO & Director | Richard Gerald Adcock |
|---|---|
| Founder, Executive Chairman and Global Chief Scientific & Medical Officer | Patrick Soon-Shiong F.A.C.S., FRCS (C), M.D., M.S., M.Sc. |
| Chief Financial Officer | David C. Sachs |
| Chief Corporate Affairs Officer & Director | Barry J. Simon |
| Chief Technology Officer | Enrique Diloné Ph.D., RAC |
Major Backers & Investors (IBRX)
Notable institutional backers of ImmunityBio, Inc. include Shaw D.E. & Co., Inc., Two Sigma Investments, LP, Millennium Management, according to Nexqual as of October 23, 2026 at 10:05 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Shaw D.E. & Co., Inc. | 1.09% |
| Two Sigma Investments, LP | 1.05% |
| Millennium Management | 0.53% |
| Fidelity | 0.4% |
| Morgan Stanley | 0.32% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 3.22% |
| Vanguard Group | 3.17% |
| State Street | 2.02% |
| Geode Capital | 0.93% |
| Northern Trust | 0.34% |
Source: Nexqual, October 23, 2026 at 10:05 UTC.
From ImmunityBio, Inc.'s Latest SEC 10-K Filing (filed 2026-02-23)
Key Strengths & Strategy (as disclosed to the SEC)
- We have developed a unique ability to generate a portfolio of distinct M-ceNK cell products through the application of our proprietary technology and cytokines.
- At the core of our strategy is the Cancer BioShield™ platform, which is designed to stimulate critical lymphocytes, including natural killer (NK) cells, cytotoxic T cells, and memory T cells via our proprietary IL-15 superagonist, ANKTIVA® (nogapendekin alfa inbakicept).
- Our approach harnesses both the adaptive and innate immune systems with the goal of restoring immune function and generating lasting immunological memory in patients.
- We have developed and/or acquired rights to multiple vaccine delivery technologies for oncology to deliver common TAAs, and neoepitopes (expressed only by cancer cells) and for infectious diseases to target key viruses.
Legal & Regulatory Risks (Item 1A, quoted)
- We use the Clinic, a related party, in some of our clinical trials, which may expose us to significant regulatory risks. If our data for this site is not sufficiently robust or if there are any data integrity issues, we may be required to repeat such studies or contract with other clinical trial sites, which could delay and/or increase the cost of our development plans.
- Risks Related to Healthcare and Other Government Regulations
- Our payment obligations under the RIPA may adversely affect our financial position and results of operations and our ability to raise additional capital, which in turn may increase our vulnerability to adverse regulatory developments or economic or business downturns.
- Our clinical trials may fail to adequately demonstrate the safety and efficacy of our product candidates, which would prevent or delay regulatory approval and commercialization of other product candidates.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CYTK | Cytokinetics, Incorporated | USD 62.33 | ▼ 0.84% |
| CAI | Caris Life Sciences, Inc. | USD 31.71 | ▼ 1.98% |
| TWST | Twist Bioscience Corporation | USD 135.47 | ▼ 9.16% |
| SYRE | Spyre Therapeutics, Inc. | USD 92.33 | ▼ 0.67% |
| PTGX | Protagonist Therapeutics, Inc. | USD 139.53 | ▲ 1.05% |
| KYMR | Kymera Therapeutics, Inc. | USD 110.85 | ▼ 1.58% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:05 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt